Anti-CD79b Immunoconjugates with Cleavable Linkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for agents that specifically target CD79b for the diagnosis and treatment of CD79b-associated conditions, such as cancer, as existing technologies lack effective solutions for targeting this antigen.
Innovation Solution
Development of anti-CD79b antibodies and immunoconjugates comprising these antibodies covalently attached to cytotoxic agents like pyrrolobenzodiazepines, with specific amino acid sequences for the antibody variable regions, and a cleavable linker for targeted therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing technologies are used for targeting CD79b, then general cancer treatment approaches can be applied, but specific and effective targeting of CD79b is not achieved
Solution Approach 1:
The patent introduces anti-CD79b antibodies as intermediary molecules that specifically recognize and bind to the CD79b antigen on B-cell surfaces. These antibodies serve as mediators between the therapeutic agent and the target cells, enabling selective targeting of CD79b-positive cancers while sparing other cell types. The antibodies can be conjugated to cytotoxic agents, radioisotopes, or other therapeutic molecules to deliver targeted therapy.
Solution Approach 2:
The invention applies local quality by designing therapeutic agents with specific binding properties for CD79b-expressing cells. The anti-CD79b antibodies exhibit high affinity and specificity for their target antigen, concentrating the therapeutic effect locally at the site of CD79b-positive tumor cells. This localized action maximizes therapeutic effectiveness while minimizing off-target effects on healthy tissues.
2Object-affected harmful factors
If non-specific chemotherapy agents are used, then broad cancer cell killing is achieved, but damage to healthy cells and lack of targeted therapy occurs
Solution Approach 1:
The anti-CD79b antibody serves as a selective intermediary that guides the therapeutic agent specifically to CD79b-positive cancer cells. By conjugating the antibody to cytotoxic agents, the system ensures that the harmful substance is delivered only to target cells expressing the CD79b antigen, thereby minimizing collateral damage to healthy cells while maintaining high therapeutic concentration at the tumor site.
Solution Approach 2:
The therapeutic system exhibits local quality by concentrating the cytotoxic agent specifically at CD79b-positive tumor cells through antibody-antigen binding. This localized delivery mechanism creates a high concentration of therapeutic agent at the target site while keeping the concentration in healthy tissues negligible, thus achieving selective cytotoxicity without widespread damage to normal cells.
3Reliability
If antibody-drug conjugates are developed with specific sequences, then targeted therapy is achieved, but complexity of antibody design and manufacturing increases
Solution Approach 1:
The antibody is designed with segmented functional regions including variable domains (VH and VL) with specific hypervariable regions (HVRs) for antigen binding, and constant regions for effector functions. This segmentation allows independent optimization of binding affinity, specificity, and therapeutic activity. The modular structure facilitates rational design and engineering of antibody-drug conjugates with tailored properties for targeted therapy.
Solution Approach 2:
The invention employs parameter changes by modifying specific amino acid sequences in the antibody's hypervariable regions to optimize binding affinity and specificity for CD79b. By adjusting sequence parameters such as complementarity determining region (CDR) compositions and lengths, the antibody can be fine-tuned for maximum effectiveness while maintaining structural integrity and manufacturability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The immunoconjugates effectively bind to CD79b-positive cancer cells, inhibiting cell proliferation and providing a targeted therapeutic approach for CD79b-associated cancers, including lymphomas and leukemias.
Implementation Method 1
an antibody that binds CD79b
Implementation Method 2
the immunoconjugate comprises a cleavable linker degraded by a protease
Data Source
Figure 1A
Figure 1B
Figure 2A
AI summary
The invention provides immunoconjugates comprising anti-CD79b antibodies covalently attached to a pyrrolobenzodiazepine and methods of using the same.